As of Wednesday close, Seres Therapeutics Inc.’s (NASDAQ:MCRB) stock was down -$0.03, moving down -0.84 percent to $3.53. The average number of shares traded per day over the past five days has been 1,358,600 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.03 fall in that time frame. In the last twenty days, the average volume was 2,326,785, while in the previous 50 days, it was 2,070,782.
Since last month, MCRB stock retreated -26.92%. Shares of the company fell to $3.26 on 08/17/23, the lowest level in the past month. A 52-week high of $9.49 was reached on 04/18/23 after having rallying from a 52-week low of $3.26. Since the beginning of this year, MCRB’s stock price has dropped by -36.96% or -$2.07, and marked a new high 6 times. However, the stock has declined by -62.80% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
MCRB stock investors should be aware that Seres Therapeutics Inc. (MCRB) stock had its last reported insider trading activity 125 days ago on Apr 28. Ege David S., the of the company, disposed of 7,038 shares for $5.19 on Apr 28. It resulted in a $36,527 divestment by the insider. Ege David S. sold 5,012 shares at an average price of $7.93 on Oct 31. The insider now owns 46,734 shares following the transaction.
Valuation Metrics
The stock’s beta is 2.61. Besides these, the trailing price-to-sales (P/S) ratio of 3.47, the price-to-book (PB) ratio of 19.61.
Financial Health
In the three months ended June 29, Seres Therapeutics Inc.’s quick ratio stood at 3.20, while its current ratio was 3.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 4.46, and the total debt-to-equity ratio was 4.46. Based on annual data, MCRB earned $253.62 million in gross profit and brought in $7.13 million in revenue.
In Seres Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $100.74 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. MCRB’s revenue rose 99.04% to -$0.52 million during the quarter, while net income inched up to $126.47 million. While analysts expected Seres Therapeutics Inc. to report $0.53 quarterly earnings, the actual figure was $0.36 per share, beating the consensus estimate by -32.10%. During the quarter, the company generated $51.15 million in EBITDA. The liabilities of Seres Therapeutics Inc. were 383.77 million at the end of its most recent quarter ended June 29, and its total debt was $212.92 million. The value of shareholders’ equity is $128.21 million.
Technical Picture
This quick technical analysis looks at Seres Therapeutics Inc.’s (MCRB) price momentum. With a historical volatility rate of 11.17%, the RSI 9-day stood at 26.53% on 30 August.
With respect to its five-day moving average, the current Seres Therapeutics Inc. price is down by -0.84% percent or -$0.03. At present, MCRB shares trade -27.22% below its 20-day simple moving average and -38.82% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.26% below its SMA50 and -52.93% below its SMA200.
Stochastic coefficient K was 35.39% and Stochastic coefficient D was 27.52%, while ATR was 0.18. Given the Stochastic reading of 37.93% for the 14-day period, the RSI (14) reading has been calculated as 29.93%.
Analyst Ratings
Seres Therapeutics Inc. (MCRB) has been rated Overweight by analysts. According to 1 brokerage firm, MCRB is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Seres Therapeutics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $11.00, the current consensus forecast for the stock is $4.00 – $15.00. Based on these forecasts, analysts predict Seres Therapeutics Inc. (MCRB) will achieve an average price target of $9.83.
